KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--Apr. 2, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista's board of directors granted nine newly-hired employees inducement options to purchase an aggregate of 65,000 shares of KalVista common stock on April 1, 2024 as inducements material to each employee entering into employment with KalVista. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
馬薩諸塞州劍橋和英格蘭索爾茲伯裏--（美國商業資訊）--2024年4月2日--KalVista製藥公司（納斯達克股票代碼：KALV）今天宣佈，KalVista董事會薪酬委員會授予九名新僱員工激勵期權，於2024年4月1日購買總計65,000股KalVista普通股，作爲激勵措施，激勵每位員工在KalVista工作。期權是根據納斯達克上市規則5635（c）（4）授予的。
The options have an exercise price of $11.40 per share, which was equal to the closing price of KalVista common stock on the grant date. One-fourth of the options vest on the one-year anniversary of the vesting commencement date and the remainder vest in equal monthly installments over the next three years, in each case subject to the new employee's continued service with the company. Each stock option has a 10-year term and is subject to the terms and conditions of KalVista's Inducement Equity Incentive Plan and a stock option agreement covering the grant.
這些期權的行使價爲每股11.40美元，等於授予日KalVista普通股的收盤價。四分之一的期權在歸屬開始日期一週年之際歸屬，其餘期權在未來三年內按月等額分期歸屬，每種情況都取決於新員工在公司的持續服務。每個股票期權的期限爲10年，並受KalVista的激勵股權激勵計劃的條款和條件以及涵蓋該贈款的股票期權協議的約束。
About KalVista Pharmaceuticals, Inc.
關於 KalVista 製藥公司
KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors for diseases with significant unmet need. KalVista disclosed positive phase 3 data for the KONFIDENT trial for its oral, on-demand therapy sebetralstat in February 2024. The Company anticipates submitting a new drug application to the U.S. FDA for sebetralstat in the first half of 2024 and expects to file for approval in Europe and Japan later in 2024. In addition, KalVista's oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve the treatment for people living with HAE and other diseases.
KalVista Pharmaceuticals, Inc. 是一家制藥公司，專注於口服小分子蛋白酶抑制劑的發現、開發和商業化，用於有大量未滿足需求的疾病。KalVista於2024年2月披露了其口服按需療法sebetralstat的KONFIDENT試驗的3期陽性數據。該公司預計在2024年上半年向美國食品藥品管理局提交sebetralstat的新藥申請，並預計將於2024年晚些時候在歐洲和日本申請批准。此外，KalVista的口服因子XiA抑制劑計劃代表了新一代療法，可能會進一步改善HAE和其他疾病患者的治療。
For more information about KalVista, please visit www.kalvista.com
有關 KalVista 的更多信息，請訪問 www.kalvista.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240402778985/en/
KalVista Pharmaceuticals, Inc.
Jarrod Aldom
Vice President, Corporate Communications
(201) 705-0254
jarrod.aldom@kalvista.com
KalVista 製藥有限公司
賈羅德·阿爾多姆
企業傳播副總裁
(201) 705-0254
jarrod.aldom@kalvista.com
Ryan Baker
Head, Investor Relations
(617) 771-5001
ryan.baker@kalvista.com
瑞安·貝克
投資者關係主管
(617) 771-5001
ryan.baker@kalvista.com
Source: KalVista Pharmaceuticals, Inc.
資料來源：KalVista 製藥公司
譯文內容由第三人軟體翻譯。